FACULTY

Julie M. Vose, MD - Chair
Neumann M. and Mildred E. Harris Professor
Chief, Section of Oncology/Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Andre Goy, MD, MS
Chief, Lymphoma Division
Director, Tumor Bank and Genomics Program
The Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey

John P. Leonard, MD
Richard T. Silver Distinguished Professor of
Hematology and Medical Oncology
Clinical Director, Center for Lymphoma and Myeloma
Associate Director for Clinical Research
Weill Cornell Cancer Center
Professor of Medicine, Weill Cornell Medical College
Attending Physician, NewYork-Presbyterian Hospital
New York, New York

Thomas E. Witzig, MD
Consultant in Hematology
Professor of Medicine
Mayo Clinic College of Medicine
Mayo Clinic
Rochester, Minnesota

FEATURED LECTURES

This activity is jointly sponsored by the University of Nebraska Medical Center, Center for Continuing Education and Educational Concepts Group, LLC

This activity is supported by an unrestricted educational grant from Celgene Corporation

Estimated time to complete activity: 2.0 hours | Release Date: July 1, 2009 | Expiration Date: June 30, 2010
This activity may be accessed at www.educationalconcepts.net.

The treatment of aggressive lymphoma remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this disease. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise, and available health-system resources. While difficult, these decisions require knowledge of current clinical and experimental data in order for the appropriate utilization of therapeutic agents and strategies in clinical practice. This educational program provides participants with an overview of the most recent advances in the treatment of aggressive lymphoma, as well as specific updates and outcomes of ongoing clinical trials, synthesized into a concise learning opportunity by experts in the field. The cutting-edge data these experts will present will provide practitioners with the information they need to incorporate new therapeutic strategies into their patient care decisions. As a result, it will lead to improved response and survival rates for patients with aggressive lymphoma while minimizing adverse events and maintaining or improving patient quality of life.

LEARNING OBJECTIVES

The target audience for the mini symposium includes hematologists, hematologist-oncologists, pathologists, clinical scientists, nurses, allied healthcare professionals caring for patients with lymphoma, and industry representatives.

Acknowledgement of Commercial Support
This activity is supported by an unrestricted educational grant from
Celgene Corporation.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF CONFLICTS OF INTEREST
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education, the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education, and the American Nurses Credentialing Center’s Commission on Accreditation must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All faculty and planning committee members participating in a University of Nebraska Medical Center, Center for Continuing Education, University of Nebraska Medical Center, College of Nursing Continuing Nursing Education, and American Nurses Credentialing Center’s Commission on Accreditation activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity includes presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. Likewise, it is incumbent upon faculty to verbally disclose such interests/commitments at the beginning of their presentation at the educational activity.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education, University of Nebraska Medical Center, College of Nursing Continuing Nursing Education, or American Nurses Credentialing Center’s Commission on Accreditation.

The following faculty members have declared relevant financial relationships:

Julie M. Vose, MD - Chair
Grants/Research Support
Allos Therapeutics, Inc., Astellas Pharma, Inc., Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals, Novartis

Andre Goy, MD, MS
Honorarium
Biogen Idec, Genentech BioOncology, Millennium Pharmaceuticals

John P. Leonard, MD
Consultant Fees
Biogen Idec, Celgene Corporation, Cephalon, Inc., Genentech BioOncology, GlaxoSmithKline, Immunomedics, Inc., Millennium Pharmaceuticals, Novartis, Wyeth

Thomas E. Witzig, MD
Grants/Research Support
National Cancer Institute, National Institutes of Health